Author:
Dungo Rosselle,Deeks Emma D.
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Wu SS, Frucht SJ. Treatment of Parkinson’s disease: what’s on the horizon? CNS Drugs. 2005;19(9):723–43.
2. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Expert Opin Investig Drugs. 2005;14(6):729–38.
3. Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson’s disease. Handb Exp Pharmacol. 2009;193:589–615.
4. Kyowa Hakko Kirin Co. Ltd. Approval for manufacturing and marketing of NOURIAST® tablets 20 mg, a novel antiparkinsonian agent [media release]. http://www.kyowa-kirin.com/news_releases/2013/e20130325_04.html . Accessed 25 Mar 2013.
5. Kyowa Hakko Kirin Co. Ltd. Submission of New Drug Application for Istradefylline (KW-6002), an investigational anti-Parkinson's disease drug [media release]. 27 Apr 2007. http://www.kyowa-kirin.com/news_releases/kyowa/2007/er070427_02.html .
Cited by
140 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献